Microbot Medical describes its product as "intended for use in the remote delivery and manipulation of guidewires and ...

Clearance makes Liberty the first FDA-cleared single-use, remotely operated robotic system for peripheral endovascular procedures. Microbot can now begin U.S. commercialization efforts to advance ...

Accelerated Launch Readiness Plans Position Company for Commercialization during Q4 2025The Company’s Initial Addressable Market Includes ...

Microbot Medical ( ($MBOT) ) has provided an update. On September 8, 2025, Microbot Medical announced that the FDA granted 510(k) clearance for ...

MBOT's LIBERTY robot could transform endovascular procedures. Read the full analysis on the technology and the stock here.

MBOT’s vision for the future of endovascular robotics includes autonomous capabilities, which have the potential to standardize endovascular procedures and improve access to benefit millions of ...

Microbot Medical Inc. MBOT recently signed a clinical trial agreement with the Baptist Hospital of Miami for its LIBERTY Endovascular Robotic Surgical System. The company has received the ...

HINGHAM, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (MBOT), developer of the innovative LIBERTY ® Endovascular Robotic System, announced its participation in the inaugural ...

Microbot Medical (MBOT) announced that the U.S. Food and Drug Administration has granted 510(k) clearance for the LIBERTY System, the first FDA ...